OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	783
Antibody treatment to deplete transthyretin amyloid deposits in the heart	502
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	394
Intravascular imaging improves outcomes	351
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	323
Travelling with heart failure: risk assessment and practical recommendations	303
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	300
Genetics and mechanisms of thoracic aortic disease	293
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	290
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	288
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	284
Takotsubo syndrome: pathophysiological insights and innovations in patient care	244
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	244
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	239
Alternative defibrillation strategies improve outcomes	234
Electron microscopy of cardiac 3D nanodynamics: form, function, future	228
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	227
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	225
Detection of subclinical hypertrophic cardiomyopathy	206
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	204
Think Aorta: aortic dissection awareness and perspectives from the patient	202
Defining iron deficiency in patients with heart failure	198
Hallmarks of cardiovascular ageing	194
Neuromodulation reduces inflammation in HFpEF	189
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	183

CSDE1 regulates LDL receptor levels	178
Preparticipation screening reduces SCD in young athletes	168
Graded exercise therapy should not be recommended for patients with post-exertional malaise	167
LDL-cholesterol lowering with obicetrapib	165
Increased degradation of desmosomal proteins in ACM	165
No benefit of apoA-I infusion after myocardial infarction	160
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	158
Decongestion in heart failure: medical and device therapies	157
Catheter ablation improves outcomes in patients with AF and end-stage HF	157
Extracellular matrix in vascular homeostasis and disease	146
Colchicine in acute coronary syndromes: the present and the possible future	143
The oral microbiome in the pathophysiology of cardiovascular disease	135
Targeting immune cell recruitment in atherosclerosis	123
Tailored therapeutics for cardiomyopathies	122
Prevention of atherosclerosis from childhood	121
Reactive oxygen species in hypertension	120
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk	116
Donor macrophages influence rejection of transplanted hearts	112
Modelling pre-eclampsia and its cardiovascular effects	111
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	110
Cardiac sarcomere turnover by unidirectional replacement of proteins	103
RNA interference lowers triglyceride levels	103
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	103
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	102
Evidence does not support the reduction of added sugar intake from all food sources	101
Promising novel siRNA for the treatment of hypertension	101
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	97
Semaglutide is beneficial in patients with HFpEF and obesity	90
Global epidemiology of heart failure	89
Single-cell profiles of CHD and CM	87
An epigenome editing approach induces durable silencing of Pcsk9	87
BP management with a village-doctor-led strategy	86
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	85
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation	83
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	80
Development of a miniature, bioresorbable, light-activated pacemaker	79
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	79
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	79
The role of the molecular autopsy in sudden cardiac death in young individuals	77
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	77
Heart transplantation: advances in expanding the donor pool and xenotransplantation	77
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	76
CNR1 antagonism attenuates cannabis-induced atherosclerosis	74
Efferocytosis in atherosclerosis	74
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	74
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	74
New insights into dietary cholesterol absorption	74
Cardiovascular benefits of fermented foods and beverages: still up for debate	72
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	71
Mechanisms and treatment of pulmonary arterial hypertension	66

Baxdrostat beneficial in uncontrolled or resistant hypertension	64
Improving medication adherence in cardiovascular disease	64
Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	64
Gut bacteria can break down cholesterol	64
Renal denervation for hypertension	61
Cardiovascular disease and cancer: shared risk factors and mechanisms	60
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	59
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	58
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	58
Pacing with respiratory sinus arrhythmia improves outcomes in heart failure	58
Cardiac optogenetics: controlling the heart with light	57
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	55
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases	53
Epigenetic editing in cardiovascular medicine: moving beyond the hype	53
Transcriptional regulation in heart development, disease and regeneration: reassessing the fetal gene hypothesis	52
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	50
Blood pressure and its variability: classic and novel measurement techniques	50
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	49
A fresh look at coronary microembolization	49
Heart failure and obesity: novel insights leading to new treatment paradigms	47
Synthetic ion channel modulator reverses sodium channel dysfunction linked to cardiac arrhythmias	41
The need for increased pragmatism in cardiovascular clinical trials	41
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	41
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	40
The cardiac parasympathetic system has two parallel circuits	39
Black In Cardio: promoting diversity and representation in the cardiovascular field	38
Inhibiting aldosterone synthase reduces blood pressure	38
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	37
Gout flares can precede cardiovascular events	36
Sotatercept as add-on therapy for advanced PAH	36
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	36
Age-induced senescence impairs the neurovascular interface in the heart	36
Consequences of ionizing radiation exposure to the cardiovascular system	36
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	34
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	33
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	31
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	31
ASGR1 inhibition stimulates cholesterol excretion	30
Artificial intelligence-enhanced echocardiography in cardiovascular disease management	30
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	29
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	29
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	26
Surgery safer than endovascular therapy for CLTI	25
Benefit of early aortic valve surgery in asymptomatic, severe AS	23
Genome editing prevents hypertrophic cardiomyopathy in mice	23
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	22
Characterization of the F8 gene: a silver lining in a dark cloud	22
Publisher Correction: Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	22
Leadless and extravascular cardiac resynchronization therapy: the future for CRT?	22
Preserving the future of heart transplantation	21
A role for lipophagy in atherosclerosis	21
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	21
Building the Australian Cardiovascular disease Data Commons	21
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	21
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	20
High troponin I levels predict death after surgery	19
Posterior left pericardiotomy reduces AF incidence after cardiac surgery	19
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	18
The dynamic cardiac cellular landscape: visualization by molecular imaging	18
Sustained BP reduction with renal denervation	18
Charting the future of cardiology with large language model artificial intelligence	18
Alain Cribier (1945–2024)	18
Mind the gap: sex-related differences in cardiovascular disease	17
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	17
Unravelling the genetic heart–brain connection using MRI	16
Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine	16
Single-cell transcriptomics for the assessment of cardiac disease	16
Current concepts and novel targets for antiplatelet therapy	15
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group	14
The ongoing quest for the first total artificial heart as destination therapy	14
Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation	14
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	14
Cardiac splicing as a diagnostic and therapeutic target	14
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy	14
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	14